Merck Q1 2023 Report Shows Revenue Drop as COVID Treatment Sales Crash, MRK Stock Down 1%
Affected by reduced demand for Covid drug Molnupiravir, Merck has published reduced revenue figures according to its Q1 2023 report. ...
Read moreAffected by reduced demand for Covid drug Molnupiravir, Merck has published reduced revenue figures according to its Q1 2023 report. ...
Read moreFollowing the approval of the Molnupiravir Covid-19 pill by the UK medicine regulator, Merck said it is on track to ...
Read moreMerck is seeking authorization for emergency use of molnupiravir, an oral administration for early-stage COVID-19 patients. It is in talks ...
Read moreThe company plans to apply for Emergency Use Authorization (EUA) with the US FDA based on the findings of the ...
Read moreThe company plans to apply for Emergency Use Authorization (EUA) with the US FDA based on the findings of the ...
Read moreAffected by reduced demand for Covid drug Molnupiravir, Merck has published reduced revenue figures according to its Q1 2023 report....
Following the approval of the Molnupiravir Covid-19 pill by the UK medicine regulator, Merck said it is on track to...
Merck is seeking authorization for emergency use of molnupiravir, an oral administration for early-stage COVID-19 patients. It is in talks...
The company plans to apply for Emergency Use Authorization (EUA) with the US FDA based on the findings of the...
The company plans to apply for Emergency Use Authorization (EUA) with the US FDA based on the findings of the...
© 2018 JNews by Jegtheme.